Compare ASH & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASH | HRMY |
|---|---|---|
| Founded | 1924 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | N/A | 2020 |
| Metric | ASH | HRMY |
|---|---|---|
| Price | $59.28 | $37.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 9 |
| Target Price | ★ $64.29 | $51.33 |
| AVG Volume (30 Days) | ★ 997.5K | 695.1K |
| Earning Date | 01-27-2026 | 11-04-2025 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | ★ $1,824,000,000.00 | $825,944,000.00 |
| Revenue This Year | $3.34 | $23.11 |
| Revenue Next Year | $3.66 | $16.15 |
| P/E Ratio | ★ N/A | $12.04 |
| Revenue Growth | N/A | ★ 21.13 |
| 52 Week Low | $45.21 | $25.52 |
| 52 Week High | $73.31 | $40.93 |
| Indicator | ASH | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 54.65 |
| Support Level | $58.66 | $37.12 |
| Resistance Level | $59.78 | $39.60 |
| Average True Range (ATR) | 1.55 | 1.15 |
| MACD | -0.27 | -0.38 |
| Stochastic Oscillator | 47.07 | 17.33 |
Ashland Inc. is a specialty materials company serving markets including pharmaceuticals, personal care, food and beverages, coatings, construction, energy, and electronics. It operates through four segments: Life Sciences, Personal Care, Specialty Additives, and Intermediates. Life Sciences contributes the highest revenue, offering functional additives for pharmaceutical and nutrition applications. Personal Care provides ingredients for skin, hair, oral care, and household products, while Specialty Additives supplies performance-enhancing additives for coatings and. Intermediates produce BDO and related derivatives used in polymers, electronics, agriculture, and pharmaceutical applications. The company generates sales across North America, Europe, Asia Pacific, Latin America, and regions.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.